Scientists of JSC "V. G. Khlopin Radium Institute" (part of the scientific division of Rosatom) have manufactured and put into operation a pilot plant for the synthesis of sorbent for the production of a new type of gallium-68 generators. The work was carried out within the framework of the implementation of the Unified Sectoral Thematic Plan (UOTP) Rosatom State Corporation.
A radiopharmaceutical based on gallium-68 is used for the most accurate diagnosis of neuroendocrine tumors, myocardial perfusion, and prostate cancer. Radium Institute generators with advanced sorbent synthesis technology will meet the best international standards. The uniqueness of the method lies in the application of gel-spherization technology to obtain a sorbent based on titanium dioxide, which will allow synthesizing a radiopharmaceutical directly from the contents of the generator, reducing the number of production operations in clinics.
The project is able to completely cover the needs of the domestic and foreign pharmaceutical markets, increase the effectiveness and accessibility of the drug to consumers. "In addition to diagnostics, a radiopharmaceutical based on gallium-68 can be used to treat oncological and functional diseases of the body. Radionuclide has a higher contrast and resolution in imaging oncology and physiological processes compared to currently used isotopes. The scientific and technological base we have built and the flexibility of the technological process will allow us to increase the competitiveness of existing generators, as well as create next-generation generators," commented Stepan Danilov, Project Manager of JSC V.G. Khlopin Radium Institute.
Please note that this press release is based on materials provided by the company. AK&M Information Agency shall not be held liable for its contents, nor for the legal and other consequences of its publication.
